echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Top 100 global drug sales in the first three quarters of 2019

    Top 100 global drug sales in the first three quarters of 2019

    • Last Update: 2019-12-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Original: Fengyun At the top of this list is still the anti TNF α monoclonal antibody Humira (Sumeria) Although in Europe and other regions, Humira's patent has expired and some generic drugs have been listed, but in its main market in the United States, Alberta has carried out a series of patent protection measures and won almost all patent lawsuits Therefore, Humira has been in the United States in recent years The market will not be invaded by generic drugs, which will ensure that it continues to attract gold The growth rate of top 5 drugs in Q3 is very fast, and their sales in the first three quarters are more than $7.5 billion, which means that there will be five drugs with annual sales of more than $10 billion this year, let's wait and see if there will be such a "spectacular" scenario The most interesting one is keytruda of MSD Q3's sales volume is US $3.06 billion, which is due to its expanding number of indications In the third quarter of China alone, two indications were approved In the future, it will maintain rapid growth By contrast, BMS's opdivo Q3 sales are "only" US $1.817 billion, and it can now be announced that the anti-pd1 battle has ended ahead of schedule Avastin, rituxan and Herceptin, Roche's three anti-tumor drugs, are all affected by generic drugs to varying degrees, and may fall out of the top 10 in the future The growth engine of MSD is not only keytruda, but also Gardasil, a HPV vaccine for cervical cancer prevention Other fast-growing drugs include shingrix, a herpes zoster vaccine of GSK, Forteo, a peptide drug of Lilly for osteoporosis, and imfinzi, an anti PDL1 monoclonal antibody of AstraZeneca.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.